News By Tag
News By Location
Follow on Google News
Nemucore Medical Innovations, Inc. Announces Election of Independent Director
Election of James B Farinholt Jr. Gives Nemucore's Board a Majority of Independent Directors
By: Nemucore Medical Innovations, Inc.
“We are extremely pleased to welcome Jim to our Board of Directors as an independent director. He shares our vision for building a patient-centric, sustainable biopharmaceutical organization,”
Mr. Farinholt has had an extensive career in both the private and public sectors of finance and investments. Most recently he served as a founding partner at Tall Oaks Capital Partners, a regional venture capital fund focused on early stage information technology and life sciences companies in the mid-Atlantic U.S. During the 1990s, he directed numerous business development activities at Virginia Commonwealth University where he served both as Rector and later as Assistant to the President for economic development. In conjunction with his promotion of the commercialization of scientific discoveries at the University, he initiated and oversaw several start-ups; and among them was Allos Therapeutics, Inc. which he co-founded and that went public in March 2000.
His earlier years in finance included roles as an executive officer in investment banking for small and medium-sized businesses at J. P. Morgan Chase in New York and Wheat First Union and Galleher & Company in Richmond, Virginia. Among the many companies for whom he managed their public offerings was Owens & Minor, Inc. the largest distributor of medical & surgical supplies in the U.S. Jim was appointed the company’s first independent director where he served on the Executive Committee as well as compensation, finance and strategic planning committees for the maximum term allowed under the company’s corporate policies.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held biopharmaceutical clinical-stage oncology company developing innovative therapeutics, with a focus on treating multi-drug resistant cancers. Nemucore's most advanced product NMI-900, a "Best-In-Class"
Forward Looking Statement
This press release makes forward-looking statements regarding future events and our future performance about the Company’s strategy, future plans and prospects, including statements regarding the development of the Company’s therapeutic programs, the timeline for clinical development and regulatory approval of the Company’s compounds, the structure of the Company’s planned clinical trials, the Company’s rights to develop or commercialize its products, the Company’s obligations to make milestone payments and royalties and the ability of the Company to finance contemplated development activities. The words “anticipate,”